Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:31:41.636Z.
Calculation as of: 2026-10-06T20:31:41.636Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80f889fb03c5e90f23e6dbb960addb407f240d79d9565bd54dedfb6815f2f0ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Heartflow, Inc. Common Stock
Market Cap
$4.37B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.31B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.31B
Price/FCF Ratio
N/A
TTM Avg
18.04
3Y Avg
18.04
5Y Avg
18.04
Market Cap
$4.48B
Price/FCF Ratio
N/A
TTM Avg
30.17
3Y Avg
53.50
5Y Avg
47.42
Market Cap
$4.60B
Price/FCF Ratio
138.57
TTM Avg
194.41
3Y Avg
194.41
5Y Avg
194.41
Market Cap
$4.64B
Price/FCF Ratio
N/A
TTM Avg
17.05
3Y Avg
20.25
5Y Avg
24.33
Market Cap
$4.70B
Price/FCF Ratio
27.03
TTM Avg
23.99
3Y Avg
32.53
5Y Avg
32.53
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.37B | N/A | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.31B | N/A | 18.04 | 18.04 | 18.04 |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.48B | N/A | 30.17 | 53.50 | 47.42 |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 138.57 | 194.41 | 194.41 | 194.41 |
| LivaNova PLC (LIVN)vs › | $4.12B | 27.75 | 22.61 | 65.13 | 62.83 |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.11B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | N/A | 17.05 | 20.25 | 24.33 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | 27.03 | 23.99 | 32.53 | 32.53 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.02B | N/A | 19.54 | 224.11 | 224.11 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
